Fund shareholders of Intellia Therapeutics Inc
ISIN US45826J1051 · United States · LEI 5493002T5BCPE5DZC723
- Fund shareholders
- 207
- Of which ETFs
- 46 161 other funds
- Value held
- 618.2M $ 389.1K € · 4.1M SEK
- Share of capital
- 33.4 % of 140.1M shares on Jul 31, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| E*TRADE No Fee Total Market Index Fund E Trade Trust | 51 | 687.5 $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 32 | 441 $ | 0.04 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 26 | 333.3 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Avantis Total Equity Markets ETF American Century ETF Trust | 17 | 234.3 $ | 0.00 % | as of Feb 28, 2026 ↗ | |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 329K € | 0.40 % | as of Dec 31, 2025 ↗ | ||
| TOP CLASS HEALTHCARE, FI RENTA 4 GESTORA, S.G.I.I.C., S.A. | 45.9K € | 0.34 % | as of Dec 31, 2025 ↗ | ||
| A&P LIFESCIENCE FUND, FI WELZIA MANAGEMENT, SGIIC, S.A. | 14.2K € | 0.39 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| ARK Genomic Revolution ETF ARK ETF Trust | 3.82 % | as of Apr 30, 2026 ↗ |
| Tanaka Growth Fund TANAKA FUNDS INC | 3.71 % | as of Feb 28, 2026 ↗ |
| American Beacon ARK Transformational Innovation Fund AMERICAN BEACON FUNDS | 2.19 % | as of Mar 31, 2026 ↗ |
| ARK Innovation ETF ARK ETF Trust | 2.06 % | as of Apr 30, 2026 ↗ |
| WisdomTree BioRevolution Fund WisdomTree Trust | 1.48 % | as of Mar 31, 2026 ↗ |
| Global X Genomics & Biotechnology ETF GLOBAL X FUNDS | 1.19 % | as of Feb 28, 2026 ↗ |
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 1.10 % | as of Apr 30, 2026 ↗ |
| Horizon Kinetics Medical ETF Listed Funds Trust | 0.93 % | as of Mar 31, 2026 ↗ |
| Wasatch Ultra Growth Fund WASATCH FUNDS TRUST | 0.81 % | as of Mar 31, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 0.65 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 203 | +17 | 46,781,117 | +8.9 % |
| 2026Q1 | 186 | -12 | 42,967,464 | +8.3 % |
| 2025Q4 | 198 | -1 | 39,669,299 | -1.4 % |
| 2025Q3 | 199 | -4 | 40,243,836 | -6.0 % |
| 2025Q2 | 203 | -19 | 42,812,197 | +6.6 % |
| 2025Q1 | 222 | -33 | 40,156,062 | -7.9 % |
| 2024Q4 | 255 | -23 | 43,589,087 | +4.8 % |
| 2024Q3 | 278 | -13 | 41,606,724 | -4.6 % |
| 2024Q2 | 291 | +14 | 43,614,186 | +11.3 % |
| 2024Q1 | 277 | -6 | 39,187,894 | -2.6 % |
| 2023Q4 | 283 | 40,232,568 |
Institutional managers
295 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| ARK Investment Management LLC | 14,509,247 | 186M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 12,155,806 | 155.8M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 6,922,676 | 88.7M $ | as of Mar 31, 2026 |
| D. E. Shaw & Co., Inc. | 5,728,177 | 73.4M $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 4,705,901 | 60.3M $ | as of Mar 31, 2026 |
| REGENERON PHARMACEUTICALS, INC. | 3,702,995 | 47.5M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,851,472 | 36.6M $ | as of Mar 31, 2026 |
| UBS Group AG | 2,689,486 | 34.5M $ | as of Mar 31, 2026 |
| DIMENSIONAL FUND ADVISORS LP | 2,318,110 | 29.7M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 2,081,397 | 26.7M $ | as of Mar 31, 2026 |
| FMR LLC | 2,067,222 | 26.5M $ | as of Mar 31, 2026 |
| Sumitomo Mitsui Trust Group, Inc. | 1,973,061 | 25.3M $ | as of Mar 31, 2026 |
| Amova Asset Management Americas, Inc. | 1,973,061 | 25.3M $ | as of Mar 31, 2026 |
| Contrarius Group Holdings Ltd | 1,911,839 | 24.5M $ | as of Mar 31, 2026 |
| JUPITER ASSET MANAGEMENT LTD | 1,781,063 | 22.8M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 1,628,241 | 20.9M $ | as of Mar 31, 2026 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1,611,534 | 20.7M $ | as of Mar 31, 2026 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1,397,243 | 17.9M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 1,381,703 | 17.7M $ | as of Mar 31, 2026 |
| STIFEL FINANCIAL CORP | 1,012,706 | 13M $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 966,293 | 12.4M $ | as of Mar 31, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 941,285 | 12.1M $ | as of Mar 31, 2026 |
| Connor, Clark & Lunn Investment Management Ltd. | 748,636 | 9.6M $ | as of Mar 31, 2026 |
| CAPITAL FUND MANAGEMENT S.A. | 730,122 | 9.4M $ | as of Mar 31, 2026 |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 724,286 | 9.3M $ | as of Mar 31, 2026 |
Declared shareholders of Intellia Therapeutics Inc
There are 2 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Vanguard Portfolio Management | 5.30 % | 6,266,007 | as of Mar 31, 2026 · SCHEDULE 13G |
| Vanguard Capital Management | 5.03 % | 5,945,571 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of Intellia Therapeutics Inc". https://titelia.com/en/stocks/intellia-therapeutics-inc-US45826J1051